1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
656F45ECAEF57A9256525794200254097
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/oncology-market-education-timing-and-lessons-learned?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Oncology Market Education: Timing and Lessons Learned

ID: 5167


Features:

2 Info Graphics

13 Data Graphics

150+ Metrics

2 Best Practices


Pages/Slides: 26


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Timing and Lessons Learned"

STUDY OVERVIEW

Informing critical stakeholders about new therapies is an important part of any new product launch - and new oncology products are no different. As part of this effort to inform the marketplace, it is important to target the right stakeholder segments at the appropriate time. Timing is especially important for the oncology therapeutic area as launch leaders reach out to inform critical stakeholders such as thought leaders, physicians, patients, payers and advocacy groups about new oncology products.

Best Practices, LLC designed this study to determine appropriate timing for preparing the marketplace for new oncology products – through thought leader, physician, patient, and payer education and communication strategies. This study also includes a chapter with insights from launch leaders regarding lessons learned and future trends for product launches. Executives can use this study to plan and execute their programs for informing the marketplace about new oncology products.

KEY TOPICS


SAMPLE KEY METRICS
  • Development phase to start educating thought leaders
  • Development phase to start educating physicians
  • Development phase to start educating patients and advocacy groups
  • Development phase to start educating payer and government agencies
  • Percentage estimation of resource allocation for educating major market constituencies
  • Targeting the right groups for education at right time

SAMPLE KEY FINDINGS
  • Using Public Relations and Technology: New technologies and Public Relations are both “leveraged,” cost-efficient tools for education; both permit less control than companies customarily want. The development and pre-launch cycle offer many opportunities to use new technologies (e.g., social media, Internet, You Tube/video communication channels) to educate physicians, patients, payers and government.
  • Winning Payers on Board: Commence work earlier than in past to win payers, who are increasingly important to market entry in Oncology. Focus on cost and health outcomes; understand that payers need and engineer them increasingly into clinical trials.


METHODOLOGY

The benchmark class includes 34 executives and managers at 26 leading pharmaceutical, biotech and medical device companies. In addition, deep-dive executive interviews were conducted with selected participants to provide qualitative insights and emerging trends.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Service; Medical Device; Technology; Manufacturing; Consumer Products; Diagnostic; Chemical


Companies Profiled:
GlaxoSmithKline; ARIAD; Pfizer; Integrated Communications Corp.; Novartis; Genitope Corporation; NeoVista; Inc.; Amgen; Novo Nordisk; Johnson & Johnson; AstraZeneca; Roche; Lilly; Bayer; Human Genome Sciences; Boehringer Ingelheim; Nobel Biocare; Abbott; Solvay Pharmaceuticals; Genentech; Sanofi-aventis; Smith & Nephew; Amylin; Janssen Cilag Pharmaceutical; Dr Reddy's Laboratories; Spectrum Pharmaceutical


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.